Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

MRUS

Merus NV (MRUS)

Merus NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MRUS
FechaHoraFuenteTítuloSímboloCompañía
23/05/202416:00GlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
13/05/202407:00GlobeNewswire Inc.Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDANASDAQ:MRUSMerus NV
10/05/202415:33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MRUSMerus NV
09/05/202415:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
09/05/202415:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRUSMerus NV
08/05/202415:15GlobeNewswire Inc.Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateNASDAQ:MRUSMerus NV
08/05/202407:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
06/05/202415:05GlobeNewswire Inc.Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACNASDAQ:MRUSMerus NV
08/04/202411:00GlobeNewswire Inc.Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024NASDAQ:MRUSMerus NV
03/04/202407:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:MRUSMerus NV
06/03/202407:00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:MRUSMerus NV
05/03/202415:30GlobeNewswire Inc.Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionNASDAQ:MRUSMerus NV
04/03/202407:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma ConferenceNASDAQ:MRUSMerus NV
28/02/202415:55Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:MRUSMerus NV
28/02/202415:15GlobeNewswire Inc.Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
14/02/202415:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRUSMerus NV
31/01/202407:00GlobeNewswire Inc.Merus to Participate in Upcoming Investor ConferencesNASDAQ:MRUSMerus NV
15/12/202318:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRUSMerus NV
02/12/202319:40GlobeNewswire Inc.Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
26/11/202310:05GlobeNewswire Inc.Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
02/11/202315:12GlobeNewswire Inc.Merus Announces Financial Results for the Third Quarter 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
02/11/202315:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRUSMerus NV
23/10/202306:30GlobeNewswire Inc.Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ CancerNASDAQ:MRUSMerus NV
15/10/202318:58GlobeNewswire Inc.Merus Announces Business Update Conference CallNASDAQ:MRUSMerus NV
06/10/202308:32GlobeNewswire Inc.Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
11/08/202308:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
09/08/202320:53GlobeNewswire Inc.Merus Announces Pricing of Public Offering of Common SharesNASDAQ:MRUSMerus NV
09/08/202315:01GlobeNewswire Inc.Merus N.V. Announces Proposed Public Offering of Common SharesNASDAQ:MRUSMerus NV
07/08/202315:26GlobeNewswire Inc.Merus Announces Financial Results for the Second Quarter 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
28/07/202307:00GlobeNewswire Inc.Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023NASDAQ:MRUSMerus NV
 Showing the most relevant articles for your search:NASDAQ:MRUS